GSK publishes full results from elantamab mafodotin (GSK2857916) treatment OfR/R MM critical clinical study

GlaxoSmithKline (GSK), the UKPharmaceutical(http://, recently announced that it has published an assessment of B-cell mature antigen (BCMA) targeted antibodies
drug(http://conjugal (ADC) belantamab mafotin (GSK2857916) single-drug treatment recurrent or refractory The full results of the key clinical study DREAMM-2 (NCT03525678) of multiple myeloma (R/R MM)dreamM2 is a random, open label, two-arm phase II study that included 196 R/R MM patients who, despite receiving current standard treatment, had a worsening condition and a median treatment regimen of 7, Difficult to treat immunomodulating drugs and protease inhibitors, and to fight CD38 antibodies is difficult to treat and/or intolerantIn the study, patients were randomly divided into two groups and treated with a dose of 2.5 mg/kg or 3.4 mg/kg belantamab mafodotin every three weeksThe results showed that the study reached the main end point: in this refractory patient population, the total remission rate (ORR) of belantamab mafodotin (2.5 mg/kg) single-drug treatment was 31% (n-30/97), and the data were clinically significantOf the 30 patients whose condition was resustable, 18 received very good partial or better remission, including 3 with strict and complete remissionMedian follow-up for 6 months, median mitigation duration (DoR) has not yet been reached, and total lifetime (OS) has not yet been reachedSafetybelantamab mafodotin was consistent with the safety and tolerance observed in the first human clinical study DREAMM-1, with the most common level 3 or 4 adverse reactions in the 2.5mg/kg group being keracle lesions (27%), platelet reduction (20%) and anemia (20%)Patients in the DREAMM-2 study were more severe, with poorer prognosis and performance than those in the DREAMM-1 studyAnd patients in the DREAMM-2 study have previously received more treatment options than the DREAMM-1 studyThe results of the DREAMM-2 study are consistent with those of a similar subset of patients in the DREAMM-1 study